Recent Analysts’ Ratings Updates for Alphatec (ATEC)

Several analysts have recently updated their ratings and price targets for Alphatec (NASDAQ: ATEC):

• 12/15/2025 – Alphatec had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/10/2025 – Alphatec was given a new $25.00 price target on by analysts at Loop Capital.
• 12/8/2025 – Alphatec had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Alphatec was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/2/2025 – Alphatec was given a new $23.00 price target on by analysts at Morgan Stanley.
• 12/1/2025 – Alphatec had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Alphatec had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Alphatec had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – Alphatec had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/10/2025 – Alphatec had its price target raised by analysts at Morgan Stanley from $16.00 to $21.00. They now have an “equal weight” rating on the stock.
• 11/3/2025 – Alphatec had its price target raised by analysts at Barclays PLC from $22.00 to $23.00. They now have an “overweight” rating on the stock.
• 10/31/2025 – Alphatec had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $25.00 price target on the stock, up previously from $20.00.
• 10/31/2025 – Alphatec was given a new $25.00 price target on by analysts at Lake Street Capital. They now have a “buy” rating on the stock.
• 10/31/2025 – Alphatec had its price target raised by analysts at Canaccord Genuity Group Inc. from $20.00 to $25.00. They now have a “buy” rating on the stock.
• 10/31/2025 – Alphatec had its price target raised by analysts at HC Wainwright from $20.00 to $24.00. They now have a “buy” rating on the stock.
• 10/31/2025 – Alphatec had its price target raised by analysts at Needham & Company LLC from $16.00 to $22.00. They now have a “buy” rating on the stock.
• 10/28/2025 – Alphatec is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $20.00 price target on the stock.
• 10/24/2025 – Alphatec is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $19.00 price target on the stock.

Insider Buying and Selling

In related news, major shareholder Jennifer N. Pritzker sold 250,000 shares of Alphatec stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $20.80, for a total value of $5,200,000.00. Following the completion of the transaction, the insider owned 11,145,045 shares in the company, valued at $231,816,936. The trade was a 2.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey P. Rydin sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $19.32, for a total transaction of $3,864,000.00. Following the transaction, the director owned 385,441 shares of the company’s stock, valued at $7,446,720.12. This trade represents a 34.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,135,997 shares of company stock worth $63,844,738. 20.90% of the stock is owned by corporate insiders.

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.